CHRS Coherus Oncology, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Coherus Oncology, Inc. (CHRS) SEC EDGAR filings in 2026 — including a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on March 9, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Coherus Oncology, Inc. (CHRS) (SEC CIK 1512762), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 2.02: Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results released March 9, 2026
- • Full earnings details in Exhibit 99.1 — primary source for revenue, margins, and guidance figures
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Coherus Oncology, Inc. (CHRS) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 9, 2026 | — | Analysis | — |
8-K | Feb 17, 2026 | — | — | |
8-K | Feb 4, 2026 | — | — | |
8-K | Jan 23, 2026 | — | — | |
8-K | Jan 13, 2026 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 12, 2025 | Mar 31, 2025 | — | |
10-Q | Nov 6, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 8, 2024 | Jun 30, 2024 | — | |
10-Q | May 9, 2024 | Mar 31, 2024 | — | |
10-Q | Nov 6, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 2, 2023 | Jun 30, 2023 | — | |
10-Q | May 8, 2023 | Mar 31, 2023 | — | |
10-Q | Nov 8, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 4, 2022 | Jun 30, 2022 | — | |
10-Q | May 5, 2022 | Mar 31, 2022 | — | |
10-Q | Nov 8, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 5, 2021 | Jun 30, 2021 | — | |
10-Q | May 6, 2021 | Mar 31, 2021 | — | |
10-Q | Nov 5, 2020 | Sep 30, 2020 | — | |
10-Q | Aug 6, 2020 | Jun 30, 2020 | — | |
10-Q | May 7, 2020 | Mar 31, 2020 | — | |
10-Q | Nov 8, 2019 | Sep 30, 2019 | — | |
10-Q | Aug 5, 2019 | Jun 30, 2019 | — |
Frequently Asked Questions
What are the latest CHRS SEC filings in 2026?
Coherus Oncology, Inc. (CHRS) has filed a 10-Q quarterly report on November 6, 2025, an 8-K current report on March 9, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
How do I view CHRS 10-Q quarterly reports?
Coherus Oncology, Inc. (CHRS)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every CHRS 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has CHRS filed recently?
Coherus Oncology, Inc. (CHRS)'s most recent 8-K was filed on March 9, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find CHRS insider trading activity (Form 4)?
SignalX aggregates every CHRS Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does CHRS file with the SEC?
Coherus Oncology, Inc. (CHRS) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new CHRS filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Coherus Oncology, Inc. (CHRS).
What is CHRS's SEC CIK number?
Coherus Oncology, Inc. (CHRS)'s SEC CIK (Central Index Key) number is 1512762. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1512762 to look up all CHRS filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find CHRS return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Coherus Oncology, Inc. (CHRS) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Coherus Oncology, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 39+ filings.